» Articles » PMID: 32496785

Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity

Overview
Journal Mol Pharm
Specialty Pharmacology
Date 2020 Jun 5
PMID 32496785
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

ATP-binding cassette (ABC)-transporters protect tissues by pumping their substrates out of the cells in many physiological barriers, such as the blood-brain barrier, intestine, liver, and kidney. These substrates include various endogenous metabolites, but, in addition, ABC transporters recognize a wide range of compounds, therefore affecting the disposition and elimination of clinically used drugs and their metabolites. Although numerous ABC-transporter inhibitors are known, the underlying mechanism of inhibition is not well characterized. The aim of this study is to deepen our understanding of transporter inhibition by studying the molecular basis of ligand recognition. In the current work, we compared the effect of 44 compounds on the active transport mediated by three ABC transporters: breast cancer resistance protein (BCRP and ABCG2), multidrug-resistance associated protein (MRP2 and ABCC2), and P-glycoprotein (P-gp and ABCB1). Eight compounds were strong inhibitors of all three transporters, while the activity of 36 compounds was transporter-specific. Of the tested compounds, 39, 25, and 11 were considered as strong inhibitors, while 1, 4, and 11 compounds were inactive against BCRP, MRP2, and P-gp, respectively. In addition, six transport-enhancing stimulators were observed for P-gp. In order to understand the observed selectivity, we compared the surface properties of binding cavities in the transporters and performed structure-activity analysis and computational docking of the compounds to known binding sites in the transmembrane domains and nucleotide-binding domains. Based on the results, the studied compounds are more likely to interact with the transmembrane domain than the nucleotide-binding domain. Additionally, the surface properties of the substrate binding site in the transmembrane domains of the three transporters were in line with the observed selectivity. Because of the high activity toward BCRP, we lacked the dynamic range needed to draw conclusions on favorable interactions; however, we identified amino acids in both P-gp and MRP2 that appear to be important for ligand recognition.

Citing Articles

Efflux and uptake transport and gut microbial reactivation of raloxifene glucuronides.

Uoti A, Kurkela M, Niemi M, Oksanen T, Oswald S, Puustinen L Basic Clin Pharmacol Toxicol. 2024; 136(1):e14107.

PMID: 39702747 PMC: 11659111. DOI: 10.1111/bcpt.14107.


Analysing potent biomarkers along phytochemicals for breast cancer therapy: an in silico approach.

Shekar N, Vuong P, Kaur P Breast Cancer Res Treat. 2023; 203(1):29-47.

PMID: 37726449 PMC: 10771382. DOI: 10.1007/s10549-023-07107-7.


New SDS-Based Polyelectrolyte Multicore Nanocarriers for Paclitaxel Delivery-Synthesis, Characterization, and Activity against Breast Cancer Cells.

Szwed M, Michlewska S, Kania K, Szczech M, Marczak A, Szczepanowicz K Cells. 2023; 12(16).

PMID: 37626862 PMC: 10453607. DOI: 10.3390/cells12162052.


Interaction of a Homologous Series of Amphiphiles with P-glycoprotein in a Membrane Environment-Contributions of Polar and Non-Polar Interactions.

Moreno M, Filipe H, Cunha S, Ramos C, Martins P, Abel B Pharmaceutics. 2023; 15(1).

PMID: 36678803 PMC: 9862096. DOI: 10.3390/pharmaceutics15010174.


Effects of Sulforaphane-Induced Cell Death upon Repeated Passage of Either P-Glycoprotein-Negative or P-Glycoprotein-Positive L1210 Cell Variants.

Bertova A, Kontar S, Polozsanyi Z, Simkovic M, Rosenbergova Z, Rebros M Int J Mol Sci. 2022; 23(18).

PMID: 36142752 PMC: 9501161. DOI: 10.3390/ijms231810818.


References
1.
Li D, Chen L, Li Y, Tian S, Sun H, Hou T . ADMET evaluation in drug discovery. 13. Development of in silico prediction models for P-glycoprotein substrates. Mol Pharm. 2014; 11(3):716-26. DOI: 10.1021/mp400450m. View

2.
Matsuo H, Nakayama A, Sakiyama M, Chiba T, Shimizu S, Kawamura Y . ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep. 2014; 4:3755. PMC: 3895923. DOI: 10.1038/srep03755. View

3.
Paulusma C, van Geer M, Evers R, Heijn M, Ottenhoff R, Borst P . Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem J. 1999; 338 ( Pt 2):393-401. PMC: 1220065. View

4.
Giacomini K, Huang S, Tweedie D, Benet L, Brouwer K, Chu X . Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3):215-36. PMC: 3326076. DOI: 10.1038/nrd3028. View

5.
Bois F, Beney C, Boumendjel A, Mariotte A, Conseil G, di Pietro A . Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance. J Med Chem. 1998; 41(21):4161-4. DOI: 10.1021/jm9810194. View